Drug: Salirumab ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03784261 (ClinicalTrials.gov) | December 17, 2018 | 17/12/2018 | Usefulness of Non TNF Usage in RA Patients | Usefulness of Non TNF Usage in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | Drug: Drug: Salirumab;Drug: Drug: Tocilizmab;Drug: Drug: Abatacept | Shinshu University | NULL | Recruiting | 20 Years | 100 Years | All | 90 | Phase 2 | Japan |